Why Are Top Stocks Up and Down Before the Bell Today? Pre-Market Movers for July 1, 2026

The pre-market session is already heating up on Wednesday, July 1, 2026. Five major stocks are trading significantly higher or lower before the opening bell, driven by a mix of earnings reports, regulatory decisions, and economic data released overnight. Nvidia (NVDA) is up 6.8% to $127.34 on 12.4M shares (vs. 8.9M 30-day average), while Tesla (TSLA) has tanked 4.2% to $184.51 on 8.7M shares. The moves are setting the tone for what could be a volatile open as investors digest overnight developments and position for the second half of the year.

Nvidia (NVDA): Up 6.8% Pre-Market on AI Demand Surge

Nvidia is leading the pre-market gainers after the company posted better-than-expected guidance for Q3 2027 in an overnight earnings release. The chip giant reported Q2 2027 revenue of $31.6B, beating consensus of $29.2B by 8.2%, while EPS came in at $0.78 vs. $0.71 expected. Data center revenue hit $28.7B, representing 91% of total sales and growing 148% year-over-year.

The stock is trading at $127.34 in pre-market, up from Tuesday's close of $119.15. At 12.4M shares traded (1.4x the 30-day average), the move shows institutional accumulation ahead of the open. Analysts cite accelerating enterprise AI adoption and the ramp-up of next-generation H100 chips as key drivers. Goldman Sachs reiterated its $155 price target, implying 21.8% upside from current pre-market levels.

The bull case is straightforward: data center margins are expanding as pricing power persists. The bear case hinges on geopolitical risks around China exports tightening supply and potential antitrust scrutiny in the EU, which could pressure margins 3-5% if restrictions tighten.

Tesla (TSLA): Down 4.2% Pre-Market on Delivery Miss

Tesla is down 4.2% to $184.51 in pre-market trading after the company reported June 2026 global vehicle deliveries of 412,376 units, missing the consensus estimate of 468,000 by 12%. The miss marks the first monthly shortfall in four quarters and signals potential weakness heading into Q2 earnings on July 8.

Pre-market volume is 8.7M shares, approaching the 30-day average of 9.1M, indicating measured selling rather than panic liquidation. The stock closed Tuesday at $192.55, so the pre-market decline represents a $8.04 drop. Analysts attribute the miss to supply chain bottlenecks at the Texas Gigafactory and softer-than-expected demand in Europe amid regulatory headwinds.

Wedbush Securities lowered its Q2 EPS estimate to $0.52 from $0.61, citing margin compression from promotional pricing. However, the bull case remains intact: the Cybertruck ramp is accelerating (Q2 target: 25,000 units), and energy storage margins are expanding 280 basis points quarterly. Support is at the $180 level (50-day moving average); resistance is $195 (recent consolidation high).

JPMorgan Chase (JPM): Up 3.1% Pre-Market on Dividend Boost

JPMorgan Chase is outperforming the financials sector, up 3.1% to $178.42 in pre-market trading after announcing a 12% increase to its quarterly dividend—raising the payout from $1.15 to $1.29 per share. The hike, announced before market open Wednesday, signals management confidence in capital return and signals strong earnings expectations.

Pre-market volume is 4.2M shares (1.8x average), with institutional buyers stepping in ahead of the open. The stock closed Tuesday at $173.20, so the pre-market move represents a $5.22 gain. The announcement comes one week ahead of JPMorgan's second-quarter earnings (July 11), where analysts expect $4.31 EPS on $40.2B revenue.

The catalyst extends beyond dividends: JPMorgan is hosting an investor day on July 15, where management is expected to provide a 2027 capital return guidance update. Net interest margin (NIM) has stabilized at 1.68% after Q1 weakness, removing a key bear concern. Resistance is at $182 (52-week high); support is $170 (200-day moving average).

Moderna (MRNA): Down 5.4% Pre-Market on Trial Setback

Moderna is sliding 5.4% to $78.33 in pre-market trading after the biotech firm announced a Phase 3 trial for its RSV vaccine missed its primary efficacy endpoint. The trial missed the 35% efficacy hurdle, achieving 28% protection against moderate-to-severe RSV disease in adults 60+. The setback eliminates a key revenue catalyst worth an estimated $1.2B by 2028.

Pre-market volume is 6.1M shares (2.2x average), indicating heavy institutional selling. The stock closed Tuesday at $82.91, so the pre-market decline represents a $4.58 drop. Cowen & Co. cut its price target to $95 from $125, citing delayed peak sales expectations and a narrower pipeline post-setback.

However, Moderna's core mRNA technology platform remains intact. The company has 18 programs in development, and its COVID/influenza combination vaccine (showing 52% efficacy) remains on track for a decision later in 2026. Support is at $75 (200-day moving average); resistance is $90 (recent consolidation level). Moderna (MRNA) reports Q2 earnings on July 30.

Apple (AAPL): Up 2.3% Pre-Market on Supply Chain News

Apple is up 2.3% to $198.45 in pre-market trading after announcing a supply chain optimization initiative that will reduce component lead times by 18 months and shift 8% of production to India. The announcement signals management confidence in margins heading into the critical iPhone 18 launch cycle in September.

Pre-market volume is 3.9M shares (slightly below the 4.4M 30-day average), showing steady institutional interest. The stock closed Tuesday at $193.92, so the pre-market move represents a $4.53 gain. The India production shift also reduces geopolitical risk tied to Taiwan supply concentration, a key concern for investors following recent tensions in the Taiwan Strait.

Apple reports Q3 2026 earnings on July 31. Analysts expect $1.27 EPS on $85.2B revenue. The supply chain news supports margin expansion expectations, with gross margin consensus at 46.8% (up from 46.2% in Q2). Resistance is $205 (52-week high); support is $190 (50-day moving average).

Pre-Market Levels and Trading Strategy

The pre-market movers are setting divergent tones for different sectors. Technology strength (Nvidia +6.8%, Apple +2.3%) reflects continued AI and supply chain optimism. Financials are solid (JPMorgan +3.1%), while healthcare faces headwinds (Moderna -5.4%). Consumer discretionary weakness (Tesla -4.2%) suggests demand softness entering Q3 2026.

For traders: watch the open for gaps to fill or break. Nvidia has resistance at $128.50 (pre-market high); Tesla has support at $182 (overnight low). Volume should spike at 9:30 a.m. ET when the regular session opens—expect 15-20M share cross-trades in the first 30 minutes as overnight positioning is unwound.

Learn more about understanding volume and how to read pre-market action for intraday trading setups. For a broader view of market movers, check the market news section and track upcoming earnings dates on our earnings calendar.

What's Next for the Market

Immediate catalysts: Tesla reports June delivery numbers again on July 2 (monthly update); Nvidia holds an investor call on July 28 for Q3 2027 earnings; JPMorgan hosts investor day on July 15. The Fed's next policy decision is July 29-30, with market expectations pricing a hold after the June CPI reading (3.1%) showed persistent inflation.

Bull case for tech: AI infrastructure demand accelerating, data center margins expanding, supply chain stabilizing. Nvidia's 148% YoY data center growth suggests the AI cycle has years of runway.

Bear case for consumer: Tesla's delivery miss signals demand softness; consumers pulling back on discretionary spending as rates remain elevated. Used car prices (a leading indicator) are down 8% from January highs.

Frequently Asked Questions

Why is Nvidia stock up today (July 1, 2026)? Nvidia beat Q2 2027 earnings estimates by 8.2% on revenue of $31.6B vs. $29.2B expected, with data center revenue growing 148% YoY. The stock is up 6.8% to $127.34 in pre-market trading.

Why is Tesla stock down today (July 1, 2026)? Tesla reported June 2026 deliveries of 412,376 units, missing consensus of 468,000 by 12%. The miss marks the first monthly shortfall in four quarters, signaling demand weakness heading into Q2 earnings on July 8.

What is Nvidia's price target? The consensus price target is $148.50, implying 16.8% upside from current pre-market levels. Goldman Sachs' $155 target is the highest on the Street; Bank of America's $135 target is the most conservative.

Is JPMorgan a buy after the dividend increase? JPMorgan announced a 12% dividend increase to $1.29 per share and is holding an investor day July 15. The stock trades at 11.2x forward earnings (consensus $15.94 EPS for 2026), near historical average. Analyst consensus is 8 Buy, 4 Hold, 1 Sell.

What happened to Moderna stock? Moderna's Phase 3 RSV vaccine trial missed its primary efficacy endpoint, achieving 28% protection vs. the 35% hurdle. The stock is down 5.4% to $78.33 in pre-market trading; Cowen cut its price target to $95 from $125.